0000899243-22-028113.txt : 20220809 0000899243-22-028113.hdr.sgml : 20220809 20220809164813 ACCESSION NUMBER: 0000899243-22-028113 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220805 FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DEBBANE RAYMOND CENTRAL INDEX KEY: 0001053890 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 221149112 MAIL ADDRESS: STREET 1: C/O THE INVUS GROUP, LLC STREET 2: 750 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Invus US Partners LLC CENTRAL INDEX KEY: 0001839806 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 221149114 BUSINESS ADDRESS: STREET 1: 750 LEXINGTON AVE STREET 2: 30TH FL CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-371-1717 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVE STREET 2: 30TH FL CITY: NEW YORK STATE: NY ZIP: 10022 FORMER NAME: FORMER CONFORMED NAME: Invus US Partners, LLC DATE OF NAME CHANGE: 20210210 FORMER NAME: FORMER CONFORMED NAME: Invus Partners, LLC DATE OF NAME CHANGE: 20210108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ulys, L.L.C. CENTRAL INDEX KEY: 0001340098 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 221149113 BUSINESS ADDRESS: STREET 1: C/O THE INVUS GROUP, LLC STREET 2: 750 LEXINGTON AVENUE, 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-317-1717 MAIL ADDRESS: STREET 1: C/O THE INVUS GROUP, LLC STREET 2: 750 LEXINGTON AVENUE, 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER NAME: FORMER CONFORMED NAME: Ulys, LLC DATE OF NAME CHANGE: 20050928 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2445 TECHNOLOGY FOREST BLVD. STREET 2: SUITE 1100 CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 2445 TECHNOLOGY FOREST BLVD. STREET 2: SUITE 1100 CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE DATE OF NAME CHANGE: 20070426 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-05 0 0001062822 LEXICON PHARMACEUTICALS, INC. LXRX 0001839806 Invus US Partners LLC C/O THE INVUS GROUP, LLC 750 LEXINGTON AVENUE 30TH FLOOR NEW YORK NY 10022 1 0 1 0 0001340098 Ulys, L.L.C. 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022 1 0 1 0 0001053890 DEBBANE RAYMOND C/O ULYS, L.L.C. 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022 1 0 1 0 Common Stock 2022-08-05 4 P 0 147390 2.50 A 5451204 I See Footnotes Common Stock 331545 D Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock. These securities are directly held by Invus US Partners LLC These securities are directly held by Mr. Raymond Debbane. Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C. Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Artal International S.C.A. directly holds 50,859,331 shares of Issuer Common Stock; Invus, L.P. directly holds 35,402,689 shares of Issuer Common Stock; and Invus Public Equities, L.P. directly holds 3,516,214 shares of Issuer Common Stock, which securities are being reported on a separately filed Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P. Invus US Partners LLC, By: /s/ Philip Bafundo , Name: Philip Bafundo, Title: Authorized Person 2022-08-09 ULYS, L.L.C., By: /s/ Raymond Debbane, Name: Raymond Debbane, Title: President 2022-08-09 RAYMOND DEBBANE, /s/ Raymond Debbane 2022-08-09